The human defense peptide LL-37 prevents Pseudomonas aeruginosa from forming biofilms at concentrations 128 times lower than what's needed to kill the bacteria directly.
128× below MICLL-37 inhibited biofilm formation at just 0.5 µg/ml — 128 times lower than the 64 µg/ml needed to kill P. aeruginosa directly
What the researchers found
The human host defense peptide LL-37 potently inhibited Pseudomonas aeruginosa biofilm formation at a concentration of just 0.5 µg/ml — 128 times lower than the dose needed to kill bacteria outright (MIC = 64 µg/ml). This means LL-37 doesn't need to act as a direct antibiotic to fight infection; it can prevent bacteria from building the protective biofilm communities that make chronic infections so difficult to treat.
LL-37 also disrupted pre-existing biofilms and worked through multiple mechanisms: reducing bacterial attachment to surfaces, stimulating twitching motility (which keeps bacteria from settling), and downregulating quorum sensing genes in the Las and Rhl systems that bacteria use to coordinate biofilm construction.
Why it matters
Bacterial biofilms are a leading cause of chronic, hard-to-treat infections — from wound infections to lung disease in cystic fibrosis patients. Standard antibiotics often fail against biofilms because the dense bacterial communities shield individual cells. This study revealed that LL-37, a peptide our own immune system produces, has a dedicated anti-biofilm function that works at concentrations far below its antimicrobial threshold. This opens the door to developing peptide-based therapies that prevent or break down biofilms without the selective pressure that drives antibiotic resistance.
The numbers in context
Biofilm inhibition at 0.5 µg/ml · MIC = 64 µg/ml (128-fold difference) · Affected Las and Rhl quorum sensing systems · Also disrupted pre-existing biofilms
How the study worked
The researchers grew Pseudomonas aeruginosa biofilms in laboratory conditions and tested whether sub-inhibitory concentrations of LL-37 could prevent biofilm formation or disrupt existing ones. They compared LL-37 against several other antimicrobial peptides (indolicidin, CRAMP, polymyxin B, and Bac2A). Microarray gene expression analysis was used to identify which bacterial genes LL-37 affected, followed by targeted studies on bacterial attachment, twitching motility, and quorum sensing pathways.
Who was studied
Pseudomonas aeruginosa (laboratory strain)
What this study cannot tell us
This was an in vitro study using laboratory biofilm models, which may not fully replicate the complexity of biofilms in living tissue. The study focused on a single bacterial species (P. aeruginosa), so results may not generalize to all biofilm-forming organisms. Human tissue concentrations of LL-37 vary widely depending on location and health status, so the physiological relevance of the tested concentrations needs further validation in vivo.
How to read the evidence
This is an in vitro laboratory study with robust mechanistic data including microarray analysis and multiple functional assays. While the findings are compelling and well-characterized, they have not yet been validated in animal models or clinical settings, which limits the evidence grade to moderate.
When this study was published
Published in 2008, this is a foundational study in the LL-37 and biofilm field. Its findings have been widely cited and remain relevant as the basis for ongoing research into peptide-based anti-biofilm therapies.
The bigger picture
Biofilm-related infections account for up to 80% of chronic bacterial infections and are notoriously resistant to conventional antibiotics. This research reveals that human host defense peptides have evolved a sophisticated anti-biofilm capability that operates independently of their direct antimicrobial activity. Understanding this mechanism could lead to new therapeutic strategies — using peptides or peptide-mimetics at low, non-toxic doses to prevent biofilm formation in wounds, medical devices, and chronic lung infections.
Questions still open
- Can synthetic versions of LL-37 be developed that retain anti-biofilm activity while being more stable and affordable to produce?
- Does LL-37 show similar anti-biofilm effects against other clinically important biofilm-forming species like Staphylococcus aureus?
- Could topical or inhaled LL-37 formulations prevent biofilm infections on wounds or in the lungs of cystic fibrosis patients?
Common questions
What is LL-37 and why does it matter for fighting infections?
Why is preventing biofilms more important than just killing bacteria?
Read the original research
Human host defense peptide LL-37 prevents bacterial biofilm formation.
Infection and immunity, 76(9), 4176-82
Citation
Overhage, Joerg; Campisano, Andrea; Bains, Manjeet; Torfs, Ellen C W; Rehm, Bernd H A; Hancock, Robert E W. (2008). Human host defense peptide LL-37 prevents bacterial biofilm formation.. Infection and immunity, 76(9), 4176-82. https://doi.org/10.1128/IAI.00318-08